Zdrowie i gospodarka · 24/04/2018
FDA Announces Draft Guidance for Nonclinical Development of Pharmaceuticals for Severely Debilitating or Life-Threatening Hematologic Disorders
The FDA is releasing a draft guidance to help pharmaceutical companies design nonclinical studies for treatments of severely debilitating or life-threatening hematologic disorders, aiming to bring new therapies to patients sooner.